All The Efforts in One Single Objective:
To Cure Multiple Sclerosis
MULTIPLE SCLEROSIS: CHRONIC / DISABLING /.....

Catalonia: 8,000
Spain: 47,000
Europe: 600,000
World: 2,500,000
Conceptual Model of MS Cost Categories for Economic Burden Analysis

**Tangible Costs**
- Direct Costs
  - Medical: Physicians, Tests, Prescriptions, Hospital, Assistive devices, Therapy, Long-term care
  - Nonmedical: Home/auto modifications, Transport, Formal care, Informal care

**Indirect Costs**
- Increased Mortality: Work loss, Work change

**Intangible Costs**
- Pain, suffering
- Quality of life impacts
- Stress
- Quality of life impact on family/friends

- Impact on Family and Friends: Employment changes, Health effects
- Early Mortality: Earnings losses

26,000 USD/year (26-87% total)
17,000 USD/year (13-74% total)

Adapted from MSIF 2010
MS therapies: targeting symptoms

Research rough indicators

Patents (WIPO)
3029 PCTs until dec 2015
filled by 702 companies & institutions

Clinical Trials (clinicaltrial.gov).
766 studies phase 0-III
145 studies currently open
Who is GAEM?

OBJECTIVES

The GAEM Foundation was established in 2006 by a group of Multiple Sclerosis sufferers with the aim of promoting biomedical research into the disease. It is an independent, non-profit, private foundation.

- Bring possible solutions to MS sufferers by accelerating research projects.
- Involve the private sector and institutions in the fight against MS.
- Provide information and support to those affected and their families.
- Raise awareness about the disease.
NEW WAYS TO FACING MS INNOVATION

USA
MS Research center of NY (http://tischms.org/)
MS Research Institute (http://www.msresearchinstitute.org/)
Accelerated Cure Project (http://www.acceleratedcure.org/)

UK
MS Research training & Education (http://www.ms-research.org.uk/)
MS Trust funded research (http://www.mstrust.org.uk/research/mstrustprojects/)

Barcelona
GAEM (http://www.fundaciongaem.org/)
Philantropy donations to science & research in Spain as low as 6%
Our aim is shortening as much as possible the time to reach the patients.
GAEM SCIENTIFIC COMMITTEE

ISIDRE FERRER
Director of the Institute of Neuropathology and the Bellvitge University Hospital Brain Bank

JOAN BIGORRA
Director of Innovation at the Hospital Clinic of Barcelona

JOAQUIM TRIAS
Founder of JTPS Consulting

LUIS RUIZ
CEO of Spherium Biomed

PAU BRUGUERA
Director de R&D at Biokit

ANDREU VEÀ
Digital Champion for Spain (European Commission)

Bar graph showing:
- Biopharma: Increase 15%, Decrease 49%
- Medical Devices: Increase 24%, Decrease 42%
- Diagnostics: Increase 30%, Decrease 21%
- Life Science Tools / Equipment: Increase 26%
- Healthcare Services / Consumer Health: Increase 42%, Decrease 54%

Legend:
- Increase
- Decrease

High FDA Regulation → Low FDA Regulation
GAEM STRONGLY SUPPORT MS INNOVATION

82% devoted to the Acceleration Program

Memoria GAEM 2015
Antigen specific therapy in Multiple Sclerosis and Neuromyelitis optica: a phase 1b clinical trial with tolerogenic dendritic cells

Irat Zubizarreta (1) - Georgina Flores (2) - Gemma Vila (1) – Raquel Cabezon (2) – Carolina España (2) – Daniel Ballesta-Ribas (2) – Sara Varela (3) – Joan Albert Anaitz (3) – Albert Salz (4) – Pablo Villalobos (1)

zubizarreta@clinic.ub.es

Introduction and objectives:
Antigen-specific therapy using tolerogenic dendritic cells has shown efficacy in animal models of MS. However, its safety and efficacy is still not tested in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMO).

To test clinically the safety and tolerability of the therapy and to see the immunological efficacy

Methods:
Study design: Phase 1b clinical trial, 12 patients (6 MS / 4 NMO).
Assessing safety protocol (1 patient per group, 2 MS & 1 NMO), 3 cell administrations, 2 weeks apart.
Assessment: clinical and immunological assessment for 3 months.

Results:
No major side effects in 6 patients (4 EM, 2 NMO) after 3 months follow-up.
Clinical variables: no changes in relapses or EDSS.

Conclusions:
Tolerized dendritic cell therapy is safe at the doses tested.
Patients receiving tolerized dendritic cells show increasing production of IL-10 after antigen removal, suggesting immune tolerization.
GAEM: BOOSTING MS AWARENESS

Redes sociales
Contacto e interacción con nuestros seguidores y la información más relevante en EM.

Seguidores
- 3,437 Facebook
- 1,378 Twitter
- 10,557 YouTube
- 65 LinkedIn

Newsletters
Información detallada de todas las actividades de GAEM y de los proyectos acelerados a los suscriptores.

1,668 SUScriptores
22% PROCEDENTes DE LA COMUNIDAD CIENTífICA
13 NEWSLETTERS CORPORATIVAS
87,5%+ RESPECTO AL 2013
GAEM: BOOSTING MS AWARENESS

X ANIVERSARY: up to 1300 people join us
GAEM AWARDS

Winner of the 1st edition of Trifermed Awards for Social Impact in Health

Winner of the 2nd edition of ‘Solidary City’ promoted by Onda Cero and Consorci Zona Franca

The “We want to live, we want to heal and we are on hurry” project won the annual edition of “Solidary Territories” promoted by Fundación BBVA y Fundación Antigues Caixes Catalanes

The “We want to live, we want to heal and we are on hurry” project won the Solidary Award conferred by Fundación Jesús Serra de la Aseguradora Catalana Occidente
THANKS FOR YOUR ATTENTION!

Mr Vicens Oliver  
President  
volver@fundaciongaem.org  
+34 935190300  
www.fundaciongaem.org

Dr. Marta Príncep  
CEO  
mprincep@fundaciongaem.org  
www.fundaciongaem.org

ALL THE EFFORTS IN ONE SINGLE OBJECTIVE: TO CURE MS